Novartis enters worldwide license agreement with PepLib

Zonsen PepLib Biotech announced that it has entered into a worldwide license agreement with Novartis (NVS) for an undisclosed peptide-based asset in the field of radioligand therapies. Under the agreement, Novartis has obtained an exclusive worldwide license and will be responsible for the development and commercialization activities for the asset. Under the terms of the agreement, PepLib will receive an upfront payment of $50M, with the potential to receive additional development, regulatory, and sales milestone payments, and is also eligible for tiered royalties on future global net sales. “Novartis is committed to expanding and strengthening our radioligand therapy portfolio to transform care for patients,” said Shiva Malek, Global Head of Oncology, Biomedical Research, Novartis. “This asset complements our industry-leading efforts to advance promising next-generation RLTs and builds on our pipeline of innovative therapies for people living with cancer.”